Drug combo shrinks melanoma tumors before surgery, study shows
NCT ID NCT02231775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two targeted drugs, dabrafenib and trametinib, given before and after surgery in 58 people with stage III melanoma that has a BRAF gene mutation. The goal was to shrink tumors before surgery and kill any remaining cancer cells afterward. The approach aims to improve the chance of staying cancer-free and reduce the amount of tissue removed during surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States